Document:

EX-4.4

 Exhibit 4.4 

LONG-TERM INCENTIVE PLAN 

SIGNA SPORTS UNITED N.V. 

ADOPTED AS OF DECEMBER 14, 2021 

INTRODUCTION 
 Article 1. 

 

	1.1	 This document sets out the Company’s long-term incentive plan for employees, officers and other service
providers who qualify as Eligible Participants. 

  

	1.2	 The main purposes of this Plan are: 

 

	 	a.	 to attract, retain and motivate Participants with the qualities, skills and experience needed to support and
promote the growth and sustainable success of the Company and its business; and 

  

	 	b.	 to incentivise Participants to perform at the highest level and to further the best interests of the Company,
its business and its stakeholders. 

 DEFINITIONS AND INTERPRETATION 

Article 2. 
  

	2.1	 In this Plan the following definitions shall apply: 

 

			
	Article	  	An article of this Plan.
		
	Award	  	A grant under this Plan in the form of one or more Options, SARs, Shares of Restricted Stock, RSUs, Other Awards, or a combination of the foregoing.
		
	Award Agreement	  	A written agreement between the Company and a Participant, evidencing the grant of an Award to such Participant and containing such terms as the Committee may determine, consistent with and subject to the terms of this
Plan.
		
	Bad Leaver	  	A Participant who ceases to be an Eligible Participant for Cause, including a situation where the Participant resigns and the Committee determines that an event has occurred with respect to that Participant which constitutes
Cause.
		
	Board	  	The Company’s board of directors.
		
	Cause	  	The occurrence of any one of the following events or such additional events set forth in a Participant’s employment, service or consulting agreement with the Company or a Subsidiary:
		
		  	 a.   such Participant’s indictment or plea of nolo contendere for any crime
which (i) constitutes a felony (or equivalent level of crime in the applicable local jurisdiction), (ii) has, or could reasonably be expected to have, an adverse impact on the performance of such Participant’s services to the Company
and/or any Subsidiary or (iii) has, or could reasonably be expected to have, an adverse impact on the business and/or reputation of the Company and/or any Subsidiary;

			
		  	 b.  such Participant having been the subject of any order, judicial or administrative,
obtained or issued by any governmental or regulatory body for any securities laws violation involving fraud, market manipulation, insider trading and/or unlawful dissemination of non-public price-sensitive
information;

		
		  	 c.   such Participant’s wilful violation of the Company’s code of
business conduct and ethics, insider trading policy or other material internal policies and regulations established by the Company and/or any Subsidiary, in each case to the extent applicable to the Participant concerned;

		
		  	 d.  gross negligence or wilful misconduct in the performance of such
Participant’s duties for the Company and/or any Subsidiary or wilful or repeated failure or refusal to perform such duties;

		
		  	 e.   material breach by such Participant of any employment, service, consulting
or other agreement entered into between such Participant on the one hand and the Company and/or any Subsidiary on the other; and

		
		  	 f.   conduct by such Participant which should be considered as an urgent cause
within the meaning of Section 7:678 DCC, irrespective of whether that provision applies to such Participant’s relationship with the Company and/or any Subsidiary

		
		  	provided that the occurrence of an event described in paragraphs c through e above shall only constitute Cause if and when such event has not been cured or remedied by the relevant Participant within thirty days after the Company
has provided written notice to such Participant describing the occurrence of an event described in paragraphs c through e above in reasonable detail (provided that the Participant shall not be given more than one opportunity to remedy failures
described in paragraphs c through e above).
		
	Change of Control	  	The occurrence of any one or more of the following events:
		
		  	 a.   the direct or indirect change in ownership or control of the Company
effected through one transaction, or a series of related transactions within a twelve-month period, as a result of which any Person or group of Persons acting in concert (other than the Company, any trustee or other fiduciary holding securities
under any employee benefit plan of the Company, or any company owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of the Company), directly or indirectly acquires
(i) beneficial ownership of more than half of the Company’s issued share capital and/or (ii) the ability to cast more than half of the voting rights in the General
Meeting;

			
		  	 b.  at any time during a period of twelve consecutive months, individuals who at the
beginning of such period constituted the Board cease to constitute a majority of members of the Board, provided that any new Director who was nominated for appointment by the Board by a vote of at least a majority of the Directors who either were
Directors at the beginning of such twelve-month period or whose nomination for appointment was so approved, shall be considered as though such individual were a Director at the beginning of such twelve-month period;

		
		  	 c.   the consummation of a merger, demerger or business combination of the
Company or any Subsidiary with another Person, unless such transaction results in the shares in the Company’s capital outstanding immediately prior to the consummation of such transaction continuing to represent (either by remaining outstanding
or by being converted into, or exchanged for, voting securities of the surviving or acquiring Person or a parent thereof) at least half of the voting rights in the General Meeting or in the shareholders’ meeting of such surviving or acquiring
Person or parent outstanding immediately after the consummation of such transaction; or

		
		  	 d.  the consummation of any sale, lease, exchange or other transfer to any Person or
group of Persons acting in concert, not being Subsidiaries, in one transaction or a series of related transactions within a twelve-month period, of all or substantially all of the assets of the Company and its Subsidiaries.

		
	Committee	  	Any committee or subcommittee the Board may appoint to administer the Plan. Subject to the discretion of the Board, the Committee shall be composed entirely of individuals who meet the qualifications of (i) a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act Securities Exchange Act of 1934, as amended from time to time and (ii) any other
qualifications required by the applicable stock exchange on which a Share is traded. If at any time or to any extent the Board shall not administer the Plan, then the Plan shall be exercised by the Committee. Except as otherwise provided in the
Company’s articles of association, any action of the Committee with respect to the administration of the Plan shall be taken by a majority vote at a meeting at which a quorum is duly constituted or unanimous written consent of the
Committee’s members.
		
	Company	  	SIGNA Sports United N.V.
		
	Consultant	  	Any Person, other than a Director or Employee, who is an adviser or consultant engaged by the Company and/or a Subsidiary to render bona fide services to the Company and/or a Subsidiary.
		
	DCC	  	The Dutch Civil Code.

			
	Director	  	A member of the Board.
		
	Eligible Participant	  	Any Director, Employee or Consultant.
		
	Effective Date	  	The date the Plan became effective which is December 14, 2021.
		
	Employee	  	Any Person, other than a Director, who is an employee or officer of the Company and/or a Subsidiary.
		
	Exercise Date	  	The date on which an Award is duly exercised by or on behalf of the Participant concerned.
		
	Exercise Price	  	The exercise price applicable to an Award.
		
	FMV	  	The closing price of a Share on the relevant date (or, if there is no reported sale of Shares on such date, on the last preceding date on which any such reported sale occurred) on the principal stock exchange where Shares have been
admitted for trading, unless determined otherwise by the Committee.
		
	General Meeting	  	The Company’s general meeting of shareholders.
		
	Good Leaver	  	A Participant who ceases to be an Eligible Participant and who is not a Bad Leaver.
		
	Grant Date	  	The date on which the Committee decides to grant an Award, or such later effective date applicable to such Award as may be determined by the Committee.
		
	Option	  	The right to subscribe for, or otherwise acquire, one Plan Share.
		
	Other Award	  	An Award which does not take the form of an Option, SAR, Share of Restricted Stock or RSU, and which may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares or factors
which may influence the value of Shares, including cash-settled financial instruments and financial instruments which are convertible into or exchangeable for Plan Shares.
		
	Participant	  	The holder of an Award, including, as the context may require, the rightful heir(s) of a previous holder of such Award having acquired such Award as a result of the death of such previous holder.
		
	Performance Criteria	  	The performance criteria applicable to an Award.
		
	Person	  	A natural person, partnership, company, association, cooperative, mutual insurance society, foundation or any other entity or body which operates externally as an independent unit or organisation.
		
	Plan	  	This long-term incentive plan.
		
	Plan Share	  	A Share reserved for issuance under the Plan, as adjusted pursuant to the Plan, and any successor (pursuant to a merger, consolidation or other reorganization) security.
		
	Replacement Award	  	An Award granted in assumption of, or in substitution or exchange for, long-term incentive awards previously granted by a Person acquired (or whose business is acquired) by the Company or a Subsidiary or with which the Company or a
Subsidiary merges or forms a business combination, as reasonably determined by the Committee.

			
	Restricted Stock	  	Plan Shares subject to such restrictions as the Committee may impose, including with respect to transferability, voting rights and the right to receive dividends or other distributions made by the Company.
		
	RSU	  	The right to receive, in cash, in assets, in the form of Plan Shares valued at FMV, or a combination thereof, the FMV of one Share on the Exercise Date.
		
	SAR	  	The right to receive, in cash, in assets, in the form of Plan Shares valued at FMV, or a combination thereof, the excess of the FMV of one Share on the applicable Exercise Date over the applicable Exercise Price.
		
	Section 409A IRC	  	Section 409A of the United States Internal Revenue Code of 1986, as amended, and the rules, regulations and guidance promulgated pursuant thereto (or any successor provision).
		
	Section 457A IRC	  	Section 457A of the United States Internal Revenue Code of 1986, as amended, and the rules, regulations and guidance promulgated pursuant thereto (or any successor provision).
		
	Share	  	An ordinary share in the Company’s capital.
		
	Share Reserve	  	The maximum number of Shares reserved for issuance under the Plan.
		
	Subsidiary	  	A subsidiary of the Company within the meaning of Section 2:24a DCC.

  

	2.2	 References to statutory provisions are to those provisions as they are in force from time to time.

  

	2.3	 Terms that are defined in the singular have a corresponding meaning in the plural. 

 

	2.4	 Words denoting a gender include each other gender. 

 

	2.5	 Except as otherwise required by law, the terms “written” and “in writing” include the use
of electronic means of communication. 

 ADMINISTRATION 

Article 3. 
  

	3.1	 This Plan shall be administered by the Committee. The Committee’s powers and authorities under this Plan
include the authority to perform the following matters, in each case consistent with and subject to the terms of this Plan: 

  

	 	a.	 designating Persons to whom Awards are granted; 

 

	 	b.	 deciding to grant Awards; 

 

	 	c.	 determining the form(s) and type(s) of Awards being granted and setting the terms and conditions applicable to
such Awards, including: 

  

	 	i.	 the number of Plan Shares underlying Awards; 

 

	 	ii.	 the time(s) when Awards may be exercised or settled in whole or in part; 

	 	iii.	 whether, to which extent, and under which circumstances Awards may be exercised or settled in cash or assets
(including other Awards), or a combination thereof, in lieu of Plan Shares and vice versa; 

  

	 	iv.	 whether, to which extent and under which circumstances Awards may be cancelled or suspended;

  

	 	v.	 whether, to which extent and under which circumstances a Participant may designate another Person owned or
controlled by him as recipient or beneficiary of his Awards; 

  

	 	vi.	 whether and to which extent Awards are subject to Performance Criteria and/or restrictive covenants (including non-competition, non-solicitation, confidentiality and/or Share ownership requirements); 

 

	 	vii.	 the method(s) by which Awards may be exercised, settled or cancelled; 

 

	 	viii.	 whether, to which extent and under which circumstances, the exercise, settlement or cancellation of Awards may
be, accelerated, deferred or suspended; 

  

	 	d.	 amending or waiving the terms applicable to outstanding Awards (including Performance Criteria), subject to the
restrictions imposed by Article 9 and provided that no such amendment shall take effect without the consent of the affected Participant(s), if such amendment would materially and adversely affect the rights of the Participant(s) under such Awards,
except to the extent that any such amendment is made to cause this Plan or the Awards concerned to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations; 

 

	 	e.	 making any determination under, and interpreting the terms of, this Plan, any rules or regulations issued
pursuant to this Plan and any Award Agreement; 

  

	 	f.	 correcting any defect, supplying any omission or reconciling any inconsistency in the Plan or any Award
Agreement; 

  

	 	g.	 settling any dispute between the Company and any Participant (including any beneficiary of his Awards)
regarding the administration and operation of this Plan, any rules or regulations issued pursuant to this Plan, and any Award Agreement entered into with such Participant; and 

 

	 	h.	 making any other determination or taking any other action which the Committee considers to be necessary, useful
or desirable in connection with the administration or operation of this Plan. 

  

	3.2	 The Committee may issue further rules and regulations for the administration and operation of this Plan,
consistent with and subject to the terms of this Plan. 

  

	3.3	 All decisions of the Committee shall be final, conclusive and binding upon the Company and the Participants
(including beneficiaries of Awards). No member of the Board or the Committee, nor any officer or employee of the Company or any Subsidiary thereof acting on behalf of the Board or the Committee, shall be personally liable for any action, omission,
determination, or interpretation taken or made in good faith with respect to the Plan, and all members of the Board or the Committee and each and any officer or employee of the Company and of any Subsidiary thereof acting on their behalf shall, to
the maximum extent permitted by law, be fully indemnified and protected by the Company in respect of any such action, omission, determination or interpretation. 

 AWARDS 

Article 4. 
  

	4.1	 Awards can only be granted to Eligible Participants. 

 

	4.2	 No Award is intended to confer any rights on the relevant Participant except as set forth in the applicable
Award Agreement. In particular, no Award should be construed as giving any Participant the right to remain employed by or to continue to provide services for the Company or any Subsidiary. 

 

	4.3	 Awards shall be granted for no consideration or for such minimal cash consideration as may be required by
applicable law. 

  

	4.4	 Awards may be granted alone or in addition or in tandem with any other Award and/or any award under any other
plan of the Company or any Subsidiary. Awards granted in addition or in tandem with any other Award and/or any award under any other plan of the Company or any Subsidiary may be granted simultaneously or at different times. 

 

	4.5	 Each Award shall be evidenced by an Award Agreement entered into between the Company and the Participant
concerned. Until an Award Agreement has been entered into between the Company and the relevant Participant, no rights can be derived from the Awards concerned by such Participant. 

 

	4.6	 Plan Shares, including Awards in the form of Shares of Restricted Stock, shall be delivered in such form(s) as
may be determined by the Committee and shall be subject to such stop transfer orders and other restrictions as the Committee may deem required or advisable. Furthermore, the Committee may determine that certificates for such Shares shall bear an
appropriate legend referring to the terms, conditions and restrictions applicable thereto. 

  

	4.7	 The terms and conditions applicable to Awards, including the time(s) when Awards vest in whole or in part and
any applicable Performance Criteria, shall be set by the Committee and may vary between Awards and between Participants, as the Committee deems appropriate. The Committee may also determine whether and under which circumstances Awards shall be
settled automatically upon vesting, without being exercised by the Participant. 

  

	4.8	 The term of an Award shall be determined by the Committee, but shall not exceed ten years from the applicable
Grant Date. Unless determined otherwise by the Committee, if the exercise of an Award is prohibited by applicable law or the Company’s insider trading policy on the last business day of the term of such Award, such term shall be extended for a
period of one month following the end of such prohibition. 

  

	4.9	 Unless determined otherwise by the Committee, Awards cannot be transferred, pledged or otherwise encumbered,
except by testament or hereditary law as a result of death of the Participant concerned. 

  

	4.10	 If, as a result of changes in applicable law, accounting principles or tax rules and regulations, or due to a
variation of the composition of the Company’s issued share capital (including a share split, reverse share split, redenomination of the nominal value, or as a result of a dividend or other distribution, reorganisation, acquisition, merger,
demerger, business combination or other transaction involving the Company or a Subsidiary), an adjustment to this Plan, any Award Agreement and/or outstanding Awards is necessary to prevent dilution or enlargement of the benefits or potential
benefits intended to be made available under this Plan, the Committee may adjust equitably any or all of: 

  

	 	a.	 the number of Plan Shares available under this Plan; 

	 	b.	 the number of Plan Shares underlying outstanding Awards; and/or 

 

	 	c.	 the Exercise Price or other terms applicable to outstanding Awards. 

Such other equitable substitutions or adjustments shall be made as may be determined by the Committee, in its sole discretion. 

Without limiting the generality of the foregoing, in connection with a change in capitalization (including a Change of Control), the Committee
may provide, in its sole discretion, but subject in all events to the requirements of Section 409A IRC for U.S. Participants, for the cancellation of any outstanding Award in exchange for payment in cash or other property having an aggregate
FMV equal to the FMV of the Shares, cash or other property covered by such Award, reduced by the aggregate Exercise Price thereof, if any; provided, however, that if the Exercise Price of any outstanding Award is equal to or greater than the FMV of
the Shares, cash or other property covered by such Award, the Committee may cancel such Award without the payment of any consideration to the Participant. 
  

	4.11	 Any rights, payments and benefits under any Award shall be subject to repayment and/or recoupment by the
Company in accordance with applicable law, stock exchange rules and such policies and procedures as the Company may adopt from time to time. 

  

	4.12	 The Company may withhold from any outstanding Award, any payment, issuance or transfer to be made under such
Award, or any other compensation or amount owed by the Company to the Participant holding such Award, an amount (in cash, in assets, in the form of Shares or other Awards, or a combination thereof) equal to the withholding taxes and other costs due,
or to be withheld, by the Company or any Subsidiary in respect of the grant, exercise or settlement of such Award. 

 TYPES OF AWARDS

 Article 5. 
  

	5.1	 The Committee may grant Awards in the form of Options, SARs, Shares of Restricted Stock, RSUs, Other Awards or
a combination of the foregoing. 

  

	5.2	 Upon the exercise or settlement of vested Options, the Company shall be obliged to deliver to the Participant
concerned (or the beneficiary of such Options, as applicable), the Plan Shares underlying such Options (unless otherwise set forth in the Award Agreement). 

  

	5.3	 Upon the exercise or settlement of vested SARs, the Company shall be obliged to pay to the Participant
concerned (or the beneficiary of such SARs, as applicable) an amount equal to the number of Plan Shares underlying such SARs multiplied by the excess, if any, of the FMV of one Share on the applicable Exercise Date over the applicable specified
Exercise Price as of Grant Date. The Company may satisfy such payment obligation in cash, in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee. 

 

	5.4	 The exercise by a Participant of his rights attached to Shares of Restricted Stock shall be subject to such
restrictions as the Committee may impose, including with respect to voting rights and the right to receive dividends or other distributions made by the Company. Upon the vesting of Shares of Restricted Stock, any such restrictions and conditions
shall lapse with respect to those Shares. If an Award in the form of Shares of Restricted Stock is cancelled or otherwise terminated, the Participant shall be obliged to transfer all of his unvested Shares of Restricted Stock to the Company promptly
and for no consideration. 

	5.5	 Upon the exercise or settlement of vested RSUs, the Company shall be obliged to pay to the Participant
concerned (or the beneficiary of such RSUs, as applicable) an amount equal to the number of Plan Shares underlying such RSUs multiplied by the FMV of one Share on the applicable Exercise Date. The Company may satisfy such payment obligation in cash,
in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee (unless otherwise set forth in the Award Agreement). 

 

	5.6	 The Committee may determine that a Participant holding one or more RSUs is entitled to receive dividends and
other distributions made by the Company on the Shares, as if such Participant held the Plan Shares underlying such RSUs. The Committee may impose restrictions with respect to such entitlement. 

PERFORMANCE CRITERIA 
 Article 6. 

 

	6.1	 The Committee may condition the right of a Participant to exercise one or more of his Awards, and the timing
thereof, upon the achievement or satisfaction of such Performance Criteria as may be determined by the Committee, within periods specified by the Committee. 

  

	6.2	 If an Award is subject to Performance Criteria which must be achieved or satisfied within a period specified by
the Committee for that purpose, such Award can only be exercised or settled at or after the end of that period. 

  

	6.3	 Performance Criteria may be measured on an absolute or relative basis and may be established on a Company-wide
basis or with respect to one or more business units, divisions, Subsidiaries and/or business segments. Relative performance may be measured against a group of peer companies determined by the Committee, financial market indices and/or other
objective and quantifiable indices. Performance Criteria may relate to performance by the Company and/or by the Participant concerned. 

  

	6.4	 If the Committee determines that a change in the business, operations, group structure or capital structure of
the Company, or other events or circumstances, render certain Performance Criteria applicable to outstanding Awards unsuitable or inappropriate, the Committee may amend or waive such Performance Criteria, in whole or in part, as the Committee deems
appropriate. 

 SHARES RESERVED FOR ISSUANCE 

Article 7. 
  

	7.1	 Subject to Articles 4.10 and 7.2, the Share Reserve shall equal 33,318,017 Shares; provided, however the
Share Reserve will automatically increase on January 1st of each calendar year (each, an “Evergreen Date”), prior to the tenth anniversary of the Effective Date, in an amount
equal to the lesser of (i) 5% of the total number of Shares outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) a number of Shares determined by the
Committee. 

  

	7.2	 Plan Shares underlying Awards, which expire, which are cancelled or otherwise terminated, or which are
exercised or settled in cash or assets in lieu of Plan Shares, shall again be available under this Plan and shall not be counted towards the limit imposed by Article 7. 

VESTING, EXERCISE AND SETTLEMENT 
 Article 8. 

 

	8.1	 Each Award Agreement shall contain the vesting schedule and, where relevant, delivery schedule (which may
include deferred delivery later than the vesting dates) for the relevant Awards. 

	8.2	 Only vested Awards may be exercised or settled in accordance with their terms. An Award can only be exercised
(to the extent it is not settled automatically) by or on behalf of the Participant holding such Award. 

  

	8.3	 An Award can only be exercised through the use of an electronic system or platform to be designated by the
Committee (if and when such system or platform has been set up by the Company), or otherwise by delivering written notice to the Company in a form approved by the Committee. 

 

	8.4	 Subject to Article 9.1, the Committee shall determine the Exercise Price. 

 

	8.5	 Upon the exercise of an Award, the applicable Exercise Price must immediately be paid in cash, wire transfer of
immediately available funds or by check payable to the order of the Company, provided that the Committee, subject to applicable law, may allow such Exercise Price to be satisfied on a cashless or net settlement basis, applying any of the following
methods (or a combination thereof): 

  

	 	a.	 by means of an immediate sale by or on behalf of the relevant Participant of part of the Plan Shares underlying
the Award being exercised, with sale proceeds equal to the Exercise Price being remitted to the Company and any remaining net sale proceeds (less applicable costs, if any) being paid to such Participant; 

 

	 	b.	 by means of the relevant Participant forfeiting his entitlement to receive part of the Plan Shares underlying
the Award being exercised at FMV on the Exercise Date and charging the aggregate nominal value of the remaining Plan Shares underlying such Award against the Company’s reserves; 

 

	 	c.	 by means of the relevant Participant surrendering his entitlement to receive part of the Plan Shares underlying
the Award being exercised at FMV on the Exercise Date, against the Company becoming due an equivalent amount to such Participant and setting off that obligation against the Company’s receivable with respect to payment of the applicable Exercise
Price; or 

  

	 	d.	 by means of the relevant Participant surrendering and transferring Shares to the Company (which may include
Plan Shares underlying the Award being exercised) at FMV on the Exercise Date. 

  

	8.6	 The Company may withhold from any Award granted or any payment due or transfer made under any Award (or under
the Plan generally) or from any compensation or other amount owing to a Participant the amount (in cash, Shares, other Awards, other property, net settlement or any combination thereof) of applicable wage or withholding taxes due in respect of an
Award, its exercise or settlement or any payment or transfer under such Award (or under the Plan generally) and to take such other action, including providing for elective payment of such amounts in cash or Shares by the Participant, as may be
necessary in the option of the Company to satisfy all obligations for the payment of such taxes. In addition, the Company may cause the sale by or on behalf of the relevant Participant of part of the Plan Shares underlying any Award being exercised
or settled, with sale proceeds equal to the applicable wage or withholding taxes being remitted to the Company and any remaining net sale proceeds (less applicable costs, if any) being paid to such Participant. 

 

	8.7	 When an Award is exercised or settled in the form of Plan Shares, the Company shall, at the discretion of the
Committee, subject to applicable law and the Company’s insider trading policy: 

  

	 	a.	 issue new Plan Shares to the relevant Participant; or 

	 	b.	 transfer existing Plan Shares held by the Company to the relevant Participant, provided, in each case, that
Plan Shares may be delivered in the form of book-entry securities representing those Plan Shares (or beneficial ownership of those Plan Shares entitling the holder to exercise or direct the exercise of voting rights attached thereto) credited to the
securities account designated by the relevant Participant. Furthermore, Plan Shares may be delivered as described in the previous sentence to a Person designated by the relevant Participant, with the prior approval of the Committee, as beneficiary
of his Award. 

  

	8.8	 If an Award is exercised or settled in the form of Plan Shares and such Award does not relate to a whole number
of Plan Shares, the number of Plan Shares underlying such Award shall be rounded down to the nearest integer. 

 PRICING RESTRICTIONS
FOR OPTIONS AND SARS 
 Article 9. 
  

	9.1	 Except for Replacement Awards, the Exercise Price for an Option or SAR shall not be less than the higher of:

  

	 	a.	 the FMV of a Plan Share on the applicable Grant Date and, in case of a SAR being granted in connection with an
Option, on the Grant Date of such Option; or 

  

	 	b.	 the nominal value of a Plan Share. 

 

	9.2	 Except as provided in Article 4.10, the Committee may not, without prior approval of the General Meeting, seek
to effect any re-pricing of any outstanding “underwater” Option or SAR by: 

  

	 	a.	 amending or modifying the terms of such Award to lower the Exercise Price; 

 

	 	b.	 cancelling such Award and granting in exchange either (i) replacement Options or SARs having a lower
Exercise Price, or (ii) Restricted Stock, RSUs or Other Awards; or 

  

	 	c.	 cancelling or repurchasing such Award for cash, assets or other securities. 

 

	9.3	 Options and SARs will be considered to be “underwater” within the meaning of Article 9.2 at any time
when the FMV of the Plan Shares underlying such Awards is less than the applicable Exercise Price. 

 U.S. PARTICIPANTS 

Article 10. 
 10.1 With respect to any Award subject to
Section 409A IRC and Section 457A IRC, this Plan and the applicable Award Agreement are intended to comply with the requirements of Section 409A IRC and Section 457A IRC, the provisions of this Plan and such Award Agreement shall
be interpreted in a manner that satisfies the requirements of Section 409A IRC and Section 457A IRC, and this Plan shall be operated accordingly. If any provision of this Plan or any term or condition of any Award subject to
Section 409A IRC and Section 457A IRC would otherwise frustrate or conflict with this intent, the provision, term or condition will be interpreted and deemed amended so as to avoid this conflict. 

10.2 Notwithstanding any provision of this Plan to the contrary or any Award Agreement, a termination of employment shall not deemed to have occurred for
purposes of any provision of an Award that is subject to Section 409A IRC providing for payment upon or following a termination of a Participant’s employment unless such termination is also a “separation from service” and, for
purposes of any such provision of such Award, references to a “termination”, “termination of employment” or like terms shall mean “separation from service”. 

	10.3	 No Awards will be eligible for the payment of dividends or dividend equivalents, to the extent such Option or
SAR is subject to Section 409A IRC and Section 457A IRC. 

  

	10.4	 If all or part of any payments made, or other benefits conferred, under any Award subject to Section 409A
IRC constitutes deferred compensation for purposes of Section 409A IRC as a result of a “separation from service” of the relevant Participant (other than due to his death) within the meaning of Section 409A IRC while such
Participant is a “specified employee” under Section 409A IRC, then such payment or benefit shall not be made or conferred until six months and one business day have elapsed after the date of such “separation from service”,
except as permitted under Section 409A IRC. 

  

	10.5	 If an Award subject to Section 409A IRC includes a “series of installment payments” within the
meaning of Section 1.409A-2(b)(2)(iii) of the United States Treasury Regulations, the right of the relevant Participant to such series of installment payments shall be treated as a right to a series of
separate payments and not as a right to a single payment, and if such an Award includes “dividend equivalents” within the meaning of Section 1.409A-3(e) of the United States Treasury
Regulations, the right of the relevant Participant to such dividend equivalents shall be treated separately from the right to other amounts or other benefits under such Award. 

 

	10.6	 For any Award subject to Section 409A IRC or Section 457A IRC that provides for accelerated
distribution on a Change of Control of amounts that constitute “deferred compensation” as defined in Section 409A IRC and Section 457A IRC, if the event that constitutes such Change of Control does not also constitute a change in
the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets (in either case, as defined in Section 409A IRC), such amount shall not be distributed on such Change of Control but
instead shall vest as of the date of such Change of Control and shall be paid on the scheduled payment date specified in the applicable Award Agreement, except to the extent that earlier distribution would not result in the relevant Participant
incurring any additional tax, penalty, interest or other expense under Section 409A IRC and Section 457A IRC. 

  

	10.7	 Notwithstanding the foregoing in this Article 10, the tax treatment of the benefits provided under this Plan or
any Award Agreement is not warranted or guaranteed, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a U.S. Participant on account of non-compliance with Section 409A IRC and Section 457A IRC. 

  

	10.8	 Notwithstanding any provision of this Plan to the contrary or any Award Agreement, in the event the Committee
determines that any Award may be subject to Section 409A IRC or Section 457A IRC, the Committee may adopt such amendments to this Plan and the applicable Award Agreement or adopt other policies and procedures (including amendments,
policies and procedures with retroactive effect), or take any other actions, that the Committee determined are necessary or appropriate to: 

  

	 	a.	 exempt the Award from Section 409A IRC or Section 457A IRC and/or preserve the intended tax treatment
of the benefits provided with respect to the Award; or 

  

	 	b.	 comply with the requirements of Section 409A IRC or Section 457A IRC and thereby avoid the
application of any adverse tax consequences under such Sections. 

 LEAVER 

Article 11. 
  

	11.1	 If a Participant becomes a Good Leaver, unless otherwise determined by the Committee or set forth in an Award
Agreement: 

	 	a.	 all vested Awards that have not yet been exercised or settled must be exercised or settled in accordance with
their terms within a period specified by the Committee and, if such Awards are not exercised or (through no fault of the Participant concerned) not settled within such period, they shall be cancelled automatically without compensation for the loss
of such Awards; and 

  

	 	b.	 all unvested Awards of such Participant shall be cancelled automatically without compensation for the loss of
such Awards, unless the Committee decides otherwise. 

  

	11.2	 If a Participant becomes a Bad Leaver, all vested Awards of such Participant which have not been exercised or
settled, as well as all unvested Awards of such Participant, shall be cancelled automatically without compensation for the loss of such Awards. 

CHANGE OF CONTROL 
 Article 12. 

 

	12.1	 If long-term incentive awards are granted in assumption of, or in substitution or exchange for, outstanding
Awards in connection with a Change of Control and the Committee has determined that such awards are sufficiently equivalent to the outstanding Awards concerned, then such outstanding Awards shall be cancelled and terminated upon the replacement
awards being granted to the Participants concerned. Unless otherwise set forth in an Award Agreement, if a Participant’s employment or service is terminated by the Company, its successor or an affiliate without Cause or by the Participant on or
after a Change of Control but prior to twelve (12) months following the Change of Control, then the Participant’s outstanding Awards shall immediately vest and, where relevant, settle in full. 

 

	12.2	 If, in connection with a Change of Control, outstanding Awards are (i) not replaced by long-term incentive
awards as described in Article 12.1 or (ii) replaced by long-term incentive awards which the Committee does not consider to be sufficiently equivalent to such outstanding Awards, then such Awards shall immediately vest and, where relevant,
either (i) settle in full or (ii) be cancelled in exchange for a cash payment equal to the excess of the price per Share paid to the Company’s shareholders in connection with the Change of Control over any applicable Exercise Price,
provided that if the Exercise Price of an Award exceeds the price per Share paid to the Company’s shareholders in connection with the Change of Control, such Award may be cancelled for no consideration, unless the Committee decides otherwise.

  

	12.3	 For purposes of this Article 12, awards shall not be considered to be “sufficiently equivalent” to
outstanding Awards, if the underlying securities are not widely held and publicly traded on a regulated national stock exchange. 

  

	12.4	 For purposes of this Article 12, outstanding Awards will be considered to be substantially equivalent if,
following the Change of Control, the Award remains subject to the same terms and conditions that were applicable to the Award immediately prior to the Change of Control except that, if the Award related to Shares, the Award instead confers the right
to receive common stock of the acquiring entity (or such other form of consideration, including cash, other security or security of such other entity as may be determined by the Committee, in its sole discretion, pursuant to Article 3 hereof).

 LOCK-UP 

Article 13. 
  

	13.1	 In connection with any registration of the Company’s securities under United States securities laws, to
the extent requested by the Company or the underwriters managing any offering of the Company’s securities, and except as otherwise approved by the Committee or pursuant to any exceptions approved by such underwriters, Shares acquired by a
Participant pursuant to the issuance, vesting, exercise or settlement of any Award may not be sold, transferred, or otherwise disposed of prior to such period following the effective date of such registration as designated by such underwriters, not
to exceed 180 days following such registration. 

  

	13.2	 The Company may impose stop-transfer instructions with respect to the Shares subject to the restriction
stipulated by Article 13.1 until the end of the lock-up period referred to in that provision. 

DATA PROTECTION 
 Article 14. 

 

	14.1	 The Company may process personal data relating to the Participants in connection with the administration and
operation of this Plan. The personal data of the Participants which may be processed in this respect may include a copy of an identification document, contact details and bank and securities account numbers. Each Participant’s personal data
shall be stored by the Company for such time period as is necessary to administer such Participant’s participation in the Plan or as otherwise permitted under applicable law. 

 

	14.2	 Each Participant’s personal data shall be handled by the Company in a proper and careful manner in
accordance with applicable law, including the General Data Protection Regulation (GDPR) and the rules and regulations promulgated pursuant thereto. Participants have the right to lodge complaints with an applicable supervisory authority regarding
the Company’s processing of personal data pursuant to this Plan. 

  

	14.3	 The Company shall implement technical and organisational measures designed to protect personal data processed
pursuant to Article 14.1. Personnel or third parties that have access to such personal data shall be bound by confidentiality obligations. 

  

	14.4	 The Company shall abide by any statutory rights the Participants may have regarding their respective personal
data processed pursuant to Article 14.1, which includes the right to access, rectification, erasure, restriction of processing, objection to processing and portability of such personal data. 

 

	14.5	 In connection with the administration and operation of this Plan, the Company may transfer personal data
processed pursuant to Article 14.1 to one or more third parties, provided that there is a legitimate interest in doing so. Where such third parties are located outside the European Economic Area in countries that are not considered to provide for an
adequate level of data protection, the Company shall ensure that sufficient data protection safeguards are put in place, failing which explicit consent for such transfer shall be obtained from the Participant(s) concerned. 

 

	14.6	 The Company may establish one or more privacy policies providing further information on data protection and
applying to the processing of personal data of the Participants by the Company in connection with the administration and operation of this Plan. 

 AMENDMENTS 

Article 15. 
  

	15.1	 Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Award
Agreement, the Board may amend, supplement, suspend or terminate this Plan (or any portion thereof) pursuant to a resolution to that effect, provided that no such amendment, supplement, suspension or termination shall take effect without:

  

	 	a.	 approval of the Company’s shareholders at a General Meeting, if such approval is required by applicable
law or stock exchange rules; and/or 

  

	 	b.	 the consent of the affected Participant(s), if such action would materially and adversely affect the rights of
such Participant(s) under any outstanding Award, except to the extent that any such amendment, supplement or termination is made to cause this Plan to comply with applicable law, stock exchange rules, accounting principles or tax rules and
regulations. 

  

	15.2	 Notwithstanding anything to the contrary in the Plan, the Committee may amend the Plan and/or any Award
Agreement in such manner as may be necessary or desirable to enable the Plan and/or such Award Agreement to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in compliance with
local laws, rules and regulations to recognise differences in local law, tax policy or custom. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimise the Company’s obligation with respect to tax
equalisation for Participants on assignments outside their home country. 

 GOVERNING LAW AND JURISDICTION 

Article 16. 
 This Plan shall be governed by and shall be
construed in accordance with the laws of the Netherlands. Subject to Article 3.1 paragraph g., any dispute arising in connection with these rules shall be submitted to the exclusive jurisdiction of the competent court in Amsterdam, the Netherlands.Exhibit
10.1

 

EXCLUSIVE
REPRESENTATIVE AND LICENSE AGREEMENT

 

DUO
SCIENCES INC and LUCY PET PRODUCTS INC

 

 

THIS
EXCLUSIVE REPESENTATIVE AND LICENSE AGREEMENT (“Agreement”) is made this 18th day of April, 2022 (“Effective Date”)
by and between DUO SCIENCES INC, a subsidiary of Point of Care Nano-Technology, Inc., a Nevada corporation, with offices located in Whitehouse
Station New Jersey and Davenport, Fla., or its designee (“DUO SCIENCES” or “Company” and LUCY PET PRODUCTS or
their designee (“LUCY” or “Representative”), Limited Liability Company formed under the laws of the State of
Delaware, with an address at 31340 Via Colinas Suite 106, Westlake Village, CA 91362 USA. DUO SCIENCES and LUCY may hereafter be referred
to as the “Parties” and each a “Party”.

 

WHEREAS,
DUO SCIENCES has developed and invented certain processes and products for the pet health (see abstract of products annexed Schedule
1) (hereinafter referred to as “Products”). Products, for the purposes of this Agreement, includes any new creations related
to, developments and improvements of the Products.

 

WHEREAS,
DUO SCIENCES/Dr Blake Hawley has applied for certain patent rights, copyrights and/or trademarks regarding the products for pet health
(see patents, trademarks and copyright information annexed Schedule 2).

 

WHEREAS,
LUCY, has officers and principal owners who are experienced in the sales, distribution, and promotion of pet products domestically.

 

WHEREAS,
the parties desire to enter into an exclusive representative relationship and license agreement with each other subject to the terms
and conditions of this Agreement.

 

NOW
THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the
parties hereby agree, and covenant as follows:

 

		1.	Appointment
                                            of Exclusive Representative and Grant of License:

 

1.1       DUO
SCIENCES appoints LUCY as its exclusive representative to sell and promote its Products, subject to the terms below, in the territory
as identified in Schedule 3 annexed hereto and made a part hereof.

 

1.2       LUCY
accepts the appointment as the exclusive representative/distributor.

 

1.3       Company
grants an exclusive license to LUCY to use the formulas and Products in the subject territory for business purposes in conformity with
this Agreement, and for the term of this Agreement LUCY shall be permitted, with advance notice to Company, to sub-license the rights
granted herein to Breeder’s Choice Pet Foods, LLC to use the formulas and products. Breeder’s Choice Pet Foods, LLC shall
agree in writing to be bound by this Agreement as if it were a signatory prior to exercising any sub-licensing rights.

     

     

    

1.4       No
title or ownership interest is granted or conveyed to the Representative in the formulas or Products, including any intellectual property
arising out of such formulas or Products (“Intellectual Property’) and all Intellectual Property, pending or existing, will
remain exclusively the property of the Company, subject to the Representative’s right to purchase the Intellectual Property, formulas
and/or Products in accordance with the terms of this Agreement.

 

1.5       During
the term of this Agreement and any extensions thereof, DUO SCIENCES agrees to place the descriptions of its formulas, along with detailed
instructions about the process of creating the formulas (“Formula Information”), to LUCY. The Formula Information must contain
all information and specifications sufficient for LUCY and/or its experts to create the Products. In the event of a change of control
or sale of DUO SCIENCES, or the death or incapacity of DUO SCIENCES’s principal, Blake Hawley, LUCY shall be entitled to continue
to manufacture and sell the Products with payments due to DUO SCIENCES’s designee, the estate of Dr Blake Hawley, or successor.

 

1.6       LUCY
shall be permitted to place its name, trademark, and/or service mark on the packaging, promotional material and/or advertising (in any
media) for the Products.

 

1.7       The
term of this Agreement shall be the later of twenty years from the date of this Agreement or the expiration of the Patent issued for
the Products identified in Schedule 1.

 

		2.	Representative’s
Obligations. The Representative shall provide the following:

 

2.1       Source
ingredients, manufacture, sell and promote the Products of the Company within the territory as identified in Schedule 3.

 

2.2       Representative
shall not be required to manufacture or sell a Minimum Amount of the Products, or to purchase a minimum amount of any ingredients for
the Products.

 

2.3       Representative
shall be responsible for its packaging, promotion and sale costs as well as the shipping costs of the Product.

 

2.4       In
the event that the Representative becomes aware of any actual or potential claim against the Company by any person or entity, Representative
shall notify the Company immediately.

 

2.5
       Representative shall comply with all applicable federal, state and local laws and regulations
in performing its responsibilities hereunder.

 

2.6       At
the sole discretion of the Representative, the Representative shall devote as much time as it deems necessary to the affairs of the Company.

 

2.7       The
Representative may represent, perform services for, and sell additional products in the field as the Representative so determines, provided
the Representative’s product does not directly or indirectly compete with the Company ́s product.

 

3.            Representative’s
Right to Retain Other Representatives. The Representative, at its sole discretion and cost, shall have the right to appoint and utilize
other representatives to promote and develop the sales of the Products within the territory.

    2

     

    

4.            Company’s
Warranty and Representations. Company represents the following:

 

4.1       The
Products are safe for dogs regarding its intended usage. The Company is unaware of any material side effects arising out of the use of
the Products when fed as directed.

 

4.2       If
government approvals are necessary for marketing and sale of the Product, the Representative shall obtain such approvals at its sole
cost and expense.

 

4.3       Company
and Dr Blake Hawley represent that they, individually or collectively, own the entire right, title and interest in the Intellectual Property
(defined as including, but not limited to, the formulas, processes, patent rights, copyrights and trademarks) for the Products; the Intellectual
Property is valid and enforceable; they, individually or collectively, have the right to grant the exclusive license described in this
Agreement; the use of the Intellectual Property does not infringe upon the rights of any third party; and they are aware of no claims
against the Intellectual Property challenging the representations and warranties in this Section 4.3

 

5.            Territory
and Exclusivity of Territory.

 

5.1       The
Representative shall be the exclusive representative of the territory as identified in Schedule 3.

 

5.2       Representative
has the right to operate exclusively in the territory identified in Schedule 3, and in which the
Company is restricted from establishing any other sales representatives or agents outside the territory for the product defined in this
contract, unless agreed in writing in an addendum or separate agreement.

 

6.            Term
of Agreement, Fees and Royalties.

 

6.1       This
Agreement shall be in full force and effect commencing upon the signing of the agreement, and continue for twenty years thereafter, or
as long as the patent is in effect, unless terminated for cause, subject to Sections 8.1 and 8.2 below.

 

6.2       Representative
agrees to pay DUO SCIENCES a licensing fee and royalties as set out in Schedule 4. 

 

7.            Termination
of Agreement.

 

7.1       For
the purposes of this Agreement, this agreement may be terminated for cause by the Company if the Representative: (a) materially breaches
this Agreement after a sixty (60) day right to cure period duly noticed by the Company to the Representative in writing; (b) is convicted
of a felony related to the subject of this Agreement (c) embezzles or intentionally and wrongfully takes money or property from the Company,
(d) intentionally acts in a wrongful manner to cause pecuniary loss to the Company or (e) fails to actively promote the Product in the
Territory.

    3

     

    

7.2       For
the purposes of this Agreement, this Agreement may be terminated for cause by the Representative if the Company (a) materially breaches
this Agreement after a sixty (60) day right to cure period duly noticed by the Representative to the Company in writing; (b) if the Company
is convicted of a felony related to the subject of this Agreement; (c) intentionally acts in a wrongful manner to cause pecuniary loss
to the Representative.

 

8.            Indemnification
and Limitation of Liability.

 

8.1       Indemnification
of Company: Representative hereby agrees to indemnify, defend, and hold Company (and any parent or subsidiary now or hereafter formed)
and their respective owners, directors, officers, employees, independent contractors, and other representatives free and harmless from
any and all claims, demands, losses, costs, expenses, obligations, liabilities, damages, recoveries, and deficiencies, including interest,
penalties, attorney’s fees, and or legal costs, fees and expenses arising from or related to: (i) any breach by Representative of any
representation, warranty, covenant, obligation or agreement contained in this Agreement; (ii) any other violation of Law; and (iii) any
negligent act or omission by the Representative or Representative’s Employees.

 

8.2       Indemnification
of Representative: Company hereby agrees to indemnify, defend, and hold Representative and its directors, officers, employees, independent
contractors, and other Representatives free and harmless from any and all claims, demands, losses, costs, expenses, obligations, liabilities,
damages, recoveries, and deficiencies, including interest, penalties, attorney’s fees, and or legal costs, fees and expenses arising
from or related to: (i) any breach by Company of any representation, warranty, covenant, obligation or agreement contained in this Agreement;
(ii) any other violation of Law; (iii) any negligent act or omission by the Company or its representatives; or (iv) defects in Products
provided by Company.

 

9.            Choice
of Law and Venue.

 

9.1       The
Parties shall use their best efforts to settle any disputes, controversies, claims or differences (“disputes”) arising out
of, or in relation to, or in connection with this Agreement, or with respect to any breach, termination or claim of invalidity hereof.
To this effect they shall consult and negotiate with each other, in good faith, with a view to reach a just and equitable solution within
a period of thirty (30) calendar days after notice of a dispute by one party to the other.

 

9.2       
Dispute Resolution. Except with respect to actions for equitable relief hereunder which may be brought in a court of competent jurisdiction
within Kansas, any controversy or claim (“dispute”) arising out of or related to this Agreement shall first go to mediation.
Each Party shall equally bear the costs at such mediation. If mediation is unsuccessful, any dispute must be settled by final and binding
arbitration in the County of Douglas, Kansas, pursuant to the JAMS Foundation Comprehensive Arbitration Rules and Procedures. A single
arbitrator may be selected by unanimous agreement of the Parties, but if the Parties fail to agree on and appoint an arbitrator within
thirty (30) calendar days of the receipt by any Party of notice of the existence of a dispute, each Party shall select an arbitrator
and those arbitrators shall select a third arbitrator, who shall be appointed to arbitrate the dispute. then such dispute shall be settled
in accordance with the commercial arbitration rules then in effect of the American Arbitration Association. Any determination or award
rendered by the arbitrator(s), which may include equitable relief, shall be final, binding and conclusive upon the Parties it being understood
and agreed that the award will be the sole and exclusive remedy between them regarding any and all claims and counterclaims presented
to the tribunal and such award or determination may be entered and enforced as a final judgment in any court having jurisdiction over
the subject matter thereof or of the Parties. The prevailing party shall be awarded reasonable attorney’s fees, expert and non-expert
witness costs and expenses. All fees and expenses incurred in connection with the arbitration and the cost of the arbitrator shall be
borne by the non-prevailing party.

    4

     

    

9.3       This
Agreement shall be deemed to have been entered into in the State of Kansas, and all questions concerning the validity, interpretation
or performance of any of the terms, conditions and provisions of this Agreement or of any of the rights or obligations of the parties
shall be governed by, and resolved in accordance with, the laws of the State of Kansas.

 

10.         Force
Majeure.

 

10.1       If
any party is rendered unable, completely or partially, by the occurrence of any event of “force majeure” (hereinafter defined)
to perform such party’s obligations created by the provisions of this Agreement, other than the obligation to make payments of
money, such party shall give to the other party prompt written notice of the event of “force majeure” with reasonably complete
particulars concerning such event; thereupon, the obligations of the party giving such notice, so far as those obligations are affected
by the event of “force majeure”, shall be suspended during, but no longer than, the continuance of the event of “force
majeure.” The party affected by such event of “force majeure” shall use all reasonable diligence to resolve, eliminate
and terminate the event of “force majeure” as quickly as practicable.

 

10.2       The
requirement that an event of “force majeure” shall be remedied with all reasonable dispatch as herein above specified, shall
not require the settlement of strikes, lockouts or other labor difficulties by the party involved, contrary to such party’s wishes,
and the resolution of any and all such difficulties shall be handled entirely within the discretion of the party concerned.

 

10.3       The
term “force majeure” as used herein shall be defined as and mean any act of God, strike, civil disturbance, lockout or other
industrial disturbance, act of the public enemy, war, blockage, public riot, earthquake, tornado, hurricane, lightening, fire, public
demonstration, storm, flood, explosion, governmental action, governmental delay, restraint or inaction, unavailability of equipment,
and any other cause or event, whether of the kind enumerated specifically herein, or otherwise, which is not reasonably within the control
of the party claiming such suspension.

 

11.         Miscellaneous Clauses.

 

11.1       Change
of Control. In the event either Party experiences a change in control transaction, the terms and conditions of this Agreement shall remain
in effect and in full force, and such corporate change shall not in any way diminish, enlarge, affect or compromise the rights and obligations
defined in this agreement. For purposes of this Agreement, “change in control” transaction shall mean a merger, acquisition,
sale of assets, sale of ownership interest or any other transaction which results in a change of the power to manage the business of
a Party.

    5

     

    

11.2       Assignability.
Except as provided in Section 12.1 above, neither party shall sell, assign, transfer, convey or encumber this Agreement or any right
or interest in this Agreement or pursuant to this Agreement, or suffer or permit any such sale, assignment, transfer or encumbrance to
occur by operation of law without the prior written consent of the other party except for a change of control as defined in Section 11.1
of this Agreement. In the event of any sale, assignment, transfer or encumbrance consented to by such other party, the transferee or
such transferee’s legal representative shall agree with such other party in writing to assume personally, perform and be obligated
by the covenants, obligations, warranties, representations, terms, conditions and provisions specified in this Agreement.

 

11.3       Successors.
This Agreement and each of the provisions of this Agreement shall obligate and inure to the benefit of the heirs, executors, administrators,
successors and assigns of each of the parties; provided, however, nothing specified in this paragraph shall be a consent to the assignment
or delegation by any party of such party’s respective rights and obligations created by the provisions of this Agreement.

 

11.4       Equitable
Remedies. As a result of the uniqueness of the services to be performed by the Representative for the Company, and because the reputation
of the parties in the community may be affected by the financial success or failure of the business, in addition to the other rights
and remedies that injured party may have for a breach of this Agreement, the injured party shall have the right to: enforce this Agreement
in all of its provisions, specific performance, or other relief in a court or equity.

 

11.5       Concurrent
Remedies. No right or remedy specified in this Agreement conferred on or reserved to the parties is exclusive of any other right
or remedy specified in this Agreement or by law or equity provided or permitted; but each such right and remedy shall be cumulative of,
and in addition to, every other right and remedy specified in this Agreement or now or hereafter existing at law or in equity or by statute
or otherwise, and may be enforced concurrently therewith or from time to time. The termination of this Agreement for any reason whatsoever
shall not prejudice any right or remedy which either party may have, either at law, in equity or pursuant to the provisions of this Agreement.

 

11.6       Notices.
All notices, requests and demands pursuant to this Agreement shall be in writing and delivered (a) in person or by e-mail transmission
and shall be deemed to have been duly given on the date of service, if delivered in person or e-mail transmission (with confirmation
of transmission receipt acting as confirmation of service when sent and provided that the facsimile notices are also mailed by first
class, certified or registered mail, postage prepaid); or (b) 72 hours after mailing by first class, registered or certified mail, postage
prepaid, or (b) the next day if mailed by overnight mail with a reputable overnight carrier, and in any event, properly addressed as
follows:

 

	Company:
    

    Attn: Nicholas DeVito

    DUO SCIENCES INC

    63 Van Cleef Drive

    Whitehouse Station, NJ 08889

    Email: npdevito@gmail.com	Representative:

    Attn: Joey Herrick

    LUCY PET PRODUCTS

    31340 Via Colinas Suite 106 

    Westlake Village, CA 91362 USA

    Email: joey@lucypetproducts.com

 

or
at such other address as the party affected my designate in a written notice to such other party in compliance with this paragraph.

    6

     

    

11.7       Entire
Agreement. This Agreement supersedes any and all other agreements, either oral or in writing, between the parties regarding the subject
matter of this Agreement and specifies all the covenants and agreements between the parties with respect to that subject matter, and
each party acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party,
or anyone acting on behalf of any party, which are not specified in his Agreement; and any other agreement, statement or promise concerning
the subject matter specified in this Agreement shall be of no force or effect in a subsequent modification in writing signed by the party
to be charged.

 

11.8       Severability.
In the event any part of this Agreement, for any reason, is determined to be invalid, such determination shall not affect the validity
of any remaining portion of this Agreement, which remaining portion shall remain in complete force and effect as of this Agreement had
been executed with the invalid portion of this Agreement eliminated. It is hereby declared the intention of the parties that the parties
would have executed the remaining portion of this Agreement without including any such part, parts or portion which, for any reason,
hereafter may be determined invalid.

 

11.9       Captions
and Interpretation. Captions of the paragraphs of this Agreement are for convenience and reference only, and the words contained
in those captions shall in no way be held to explain, modify, amplify or aid in the interpretation, construction or meaning of the provisions
of this Agreement. The language in all parts to this Agreement, in all cases, shall be construed in accordance with the fair meaning
of that language as if that language was prepared by all parties and not strictly for or against any party.

 

11.10       Further
Assurances. Each party shall take any and all action necessary, appropriate or advisable to execute and discharge such party’s
responsibilities and obligations created by the provisions of this Agreement and to further effectuate, perform and carry out the intents
and purposes of this Agreement and the relationship contemplated by the provision of this Agreement.

 

11.11       Governmental
Rules and Regulations. The provisions of this Agreement are subject to any and all present and future orders, rules and regulations
of any duly constituted authority having jurisdiction of the relationship contemplated by the provisions of this Agreement.

 

11.12       Execution
in Counterparts. This Agreement may be prepared in multiple copies and forwarded to each of the parties for execution. This Agreement
shall become effective when the Representative receives a copy or copies of this Agreement executed by the parties in the names as those
names appear at the end of this Agreement. All of the signatures of the parties may be affixed to one copy or to separate copies of this
Agreement and when all such copies are received and signed by all the parties, those copies shall constitute one agreement that is not
otherwise separable or divisible.

 

11.13       Reservation
of Rights. The failure of any party at any time hereafter to require strict performance by any other party of any of the warranties,
representations, covenants, terms, conditions and provisions specified in this Agreement shall not waive, affect or diminish any right
of such failing party to demand strict compliance and performance therewith and with respect to any other provisions, warranties, terms
and conditions specified in this Agreement. None of the representations, warranties, covenants, conditions, provisions and terms specified
in this Agreement shall be deemed to have been waived by any act or knowledge of either party or such party’s agents, officers
or employees, and any such waiver shall be made only by an instrument in writing, signed by the waiving party and directed to each non-waiving
party specifying such waiver. Each party reserves such party’s rights to insist upon strict compliance with the terms, conditions,
warranties, obligations, representations, covenants and provisions of this Agreement at all times.

    7

     

    

11.14       Continuing
Provisions. Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification,
contribution and the Company’s obligations to pay fees and pay or reimburse expenses contained herein and in the indemnification,
provisions hereof will survive any such expiration or termination of this Agreement.

 

11.15       Consent
to Agreement. By executing this Agreement, each party, for itself, represents such party has read or caused to be read this Agreement
in all particulars, and consents to the rights, conditions, duties and responsibilities imposed upon such party as specified in this
Agreement.

 

Accepted
and agreed to on the date first indicated above.

 

	Company—DUO SCIENCES INC	 	Representative—LUCY PET PRODUCTS
	 	 	 
	By: Nicholas DeVito	 	By:    Joey Herrick
	Title: CEO	 	Title: CEO
	 	 	 
	By: Dr Blake Hawley	 	 

    8

     

    

SCHEDULE
1

 

Products

 

Intellectual
Property – Product commonly known as DUO

 

Abstract

 

Invention
disclosed to patent attorney for utility patent on the line of dosage form products comprised of
a hot extruded outer flexible, cellular non-GMO, non-nutritive fibrous matrix dental crust/mantle providing mechanical cleansing
action and hyper-salivation and an inner core that is cold formed and cold extruded in the center to preserve material containing various
nutraceuticals or drugs.

 

		●	Dental
                                            (equivalent to weekly brushing of teeth) + Fresh Breath - proprietary formulation
                                            plus invention disclosed to patent attorney.

 

		●	Sensitive
                                            Tummy + Dental (sensitive stomach & food/other allergies) – Epionice brand
                                            CAS United States Patent. 9,550,673, Titled: “Preservative and Additive for Food and
                                            Feed.” CEDOGA Consulting LLC licensed the material from Texas EnteroSorbents Inc on
                                            7 Nov 2017, but raw material may also be purchased outright in non-exclusive arrangement.

 

		●	Sensitive
                                            Skin & Coat/Allergy + Dental (helps reduce inflammation and improves coat luster,
                                            plus helps reduce shedding and regrow lost fur). Can be purchased outright from Eire Pharmaceuticals
                                            in accordance with exclusive licensing agreement by SBH Nutrition Science LLC. US Patent
                                            Pending

 

		●	Joint
                                            + Dental (Improves mobility & joint health in 3 days). Raw material purchased from
                                            Bioved under exclusive or non-exclusive arrangement for dogs. Artrex patent 8808769

 

		●	Calming
                                            (Cannasorb) + Dental (for owners wanting whole body benefits of CBD for calming, seizures,
                                            pain). Source of Cannasorb may be purchased outright from Synergy Life Science or substituted
                                            with CBD, which Representative may source outright.

 

		●	Weight
                                            Management + Dental (the non-nutritive weight management treat) Two options – no
                                            center (to further reduce calories)

    9

     

    

SCHEDULE
2

Patents,
Copyrights and Trademarks

 

Patent
filed on July 16, 2020, through

 

Linda
L. Lewis

Linda
Lewis, Attorney at Law, LLC

1001
Westlake Village Dr.

Pacific,
MO 63069

314-420-1525

LLewis.Law2020@gmail.com

www.LindaLewisPatentAttorney.com

 

Filing
receipt received (document follows on next page)

    10

     

    

	Electronic
    Acknowledgement Receipt
	EFS
    ID:	40019933
	Application
    Number:	16930604
	International
    Application Number:	 
	Confirmation
    Number:	3896
	Title
    of Invention:	Edible
    Pet Chew with Thermo-processed Shell and Cold-formed Filling
	First
    Named Inventor/Applicant Name:	Blake
    Hawley
	Customer
    Number:	167383
	Filer:	Linda
    L Lewis
	Filer
    Authorized By:	 
	Attorney
    Docket Number:	CCon-2UTIL
	Receipt
    Date:	16-JUL-2020
	Filing
    Date:	 
	Time
    Stamp:	13:21:34
	Application
    Type:	Utility
    under 35 USC 111(a)
	Payment
    information:
	Submitted
    with Payment	yes
	Payment
    Type	CARD
	Payment
    was successfully received in RAM	$785
	RAM
    confirmation Number	E20207FD23294677
	Deposit
    Account	 
	Authorized
    User	 
	The
    Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

    11

     

    

	 
	File
    Listing:
	Document

    Number	Document
    Description	File
    Name	File
    Size(Bytes)/

    Message Digest	Multi

    Part /.zip	Pages

    (if appl.)
	1	Application
    Data Sheet	WebADS.pdf	115456	no	7
	d6b3095ff9d177740dff54725ad9a4086027bca4
	Warnings:
	Information:
	2	 	specfiled.pdf	80241	yes	16
	d507e51f4db57877278f7824c32e614985e5829d
	 	Multipart
    Description/PDF files in .zip description
	Document
    Description	Start	End
	Specification	1	11
	Claims	12	15
	Abstract	16	16
	Warnings:
	Information:
	3	Drawings-only
    black and white line drawings	Presentation1.pdf	98844	no	3
	4ca2e64da6c33adc80397d936bd7f05e9fc8ea56
	Warnings:
	Information:
	4	 	declnpoasigned.pdf	695104	yes	6
	13ec6748a32327474d9cf4f6edc4def399e40bbb
	 	Multipart
    Description/PDF files in .zip description
	Document
    Description	Start	End
	Oath
    or Declaration filed	1	2
	 	Power
    of Attorney	3	6

    12

     

    

	Warnings:
	The
    PDF file has been signed with a digital signature and the legal effect of the document will be based on the contents of the file
    not the digital signature.
	Information:
	5	First
    Action Interview - Enrollment Request	sb0413c.pdf	735354	no	3
	96286b15d4eb80859061746c3f6972fced979d8d
	Warnings:
	Information:
	6	Fee
    Worksheet (SB06)	fee-info.pdf	35249	no	2
	2a86c79c9873072cc88ea32a27b58d5b2ac6353c
	Warnings:
	Information:
	Total Files Size (in bytes):	1760248
	This
                                            Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated
                                            documents, characterized by the applicant, and including page counts, where applicable. It
                                            serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

     

    New
    Applications Under 35 ll.S.C. 111

     

    If
    a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d)
    and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will
    establish the filing date of the application.

     

    National
    Stage of an International Application under 35 U.S.C. 371

     

    If
    a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371
    and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under
    35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

     

    New
    International Application Filed with the USPTO as a Receiving Office

     

    If
a new international application is being filed and the international application includes the necessary components for an international
filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing
Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this
Acknowledgement Receipt will establish the international filing date of the application.

 

United
States Patent and Trademark Office (USPTO)

Office
Action (Official Letter) About Applicant’s Trademark Application 

 

	U.S. Application Serial No. 88750071

                                                                                 
 Mark: DUO DOUBLE THE BENEFITS DOUBLE THE

	 
	Correspondence
    Address:

    Linda L Lewis

    Linda Lewis, Attorney at Law

    1001 Westlake Village Dr

    Pacific MO 63069
	Applicant:
    CEDOGA Consulting LLC

    13

     

    

	Reference/Docket
    No. CCon-3 TM

    Correspondence Email Address:

    LLewis.Law2020@gmail.com

 

FINAL
OFFICE ACTION

 

The
USPTO must receive applicant’s response to this letter within six months of the issue date below or the application will
be abandoned. Respond using the Trademark Electronic Application System (TEAS) and/or Electronic System for Trademark Trials and Appeals
(ESTTA). A link to the appropriate TEAS response form and/or to ESTTA for an appeal appears at the end of this Office action.

 

Issue
date:     June 25, 2020

 

INTRODUCTION

 

This
Office action is in response to applicant’s communication filed on 5-27-2020.

 

In
a previous Office action(s) dated 4-1-2020, the trademark examining attorney refused registration of the applied-for mark based on the
following: Trademark Act Section 2(d) for a likelihood of confusion with a registered mark and specimen refusal. In addition, applicant
was required to satisfy the following requirement(s): clarify the mark description and color claim and clarify ownership. Applicant was
also given the opportunity to delete the section 2(f) claim.

 

Based
on applicant’s response, the trademark examining attorney notes that the following requirement(s) have been satisfied: mark description
and color claim; ownership clarification; Section 2(f) claim is deleted. See TMEP §§713.02, 714.04.

 

The
following refusal(s) have also been obviated: Specimen refusal. See TMEP §§713.02, 714.04.

 

The
trademark examining attorney maintains and now makes FINAL the refusal under Section 2(d). See 37 C.F.R. §2.63(b); TMEP §714.04.

 

Likelihood
of Confusion

 

Registration
of the applied-for mark is refused because of a likelihood of confusion with the mark in U.S. Registration No. 4622252. Trademark Act
Section 2(d), 15 U.S.C. §1052(d); see TMEP §§1207.01 et seq.

    14

     

    

Trademark
Act Section 2(d) bars registration of an applied-for mark that is so similar to a registered mark that it is likely consumers would be
confused, mistaken, or deceived as to the commercial source of the goods and/or services of the parties.  See 15
U.S.C. §1052(d). Likelihood of confusion is determined on a case-by-case basis by applying the factors set forth in In re E.
I. du Pont de Nemours & Co., 476 F.2d 1357, 1361, 177 USPQ 563, 567 (C.C.P.A. 1973) (called the “du Pont factors”).
In re i.am.symbolic, llc, 866 F.3d 1315, 1322, 123 USPQ2d 1744, 1747 (Fed. Cir. 2017). Any evidence of record related to those
factors need be considered; however, “not all of the DuPont factors are relevant or of similar weight in every case.”
In re Guild Mortg. Co., 912 F.3d 1376, 1379, 129 USPQ2d 1160, 1162 (Fed. Cir. 2019) (quoting In re Dixie Rests., Inc.,
105 F.3d 1405, 1406, 41 USPQ2d 1531, 1533 (Fed. Cir. 1997)).

 

Although
not all du Pont factors may be relevant, there are generally two key considerations in any likelihood of confusion analysis: (1)
the similarities between the compared marks and (2) the relatedness of the compared goods and/or services. See In re i.am.symbolic,
llc, 866 F.3d at 1322, 123 USPQ2d at 1747 (quoting Herbko Int’l, Inc. v. Kappa Books, Inc., 308 F.3d 1156, 1164-65,
64 USPQ2d 1375, 1380 (Fed. Cir. 2002)); Federated Foods, Inc. v. Fort Howard Paper Co., 544 F.2d 1098, 1103, 192 USPQ 24, 29 (C.C.P.A.
1976) (“The fundamental inquiry mandated by [Section] 2(d) goes to the cumulative effect of differences in the essential characteristics
of the goods [or services] and differences in the marks.”); TMEP §1207.01.

 

Here,
as discussed in the first action, the marks are highly similar because of the shared wording DUO. DUO is the only distinctive element
of the registered mark as the wording JERKY is highly descriptive or generic of the goods and disclaimed. DUO is also the most dominant
element of applicant’s mark as DUO is very large in relation to the remaining wording and design. Registrant’s sole distinctive
element, DUO, composes the most distinctive element of applicant’s mark. This shared wording creates a clear similarity.

 

Applicant
argues that the marks are “in no way the same in appearance...” However, the question is not whether the marks are the
same but whether they are similar. The examining attorney maintains that the shared DUO creates a clear, overall, similarity.

 

Applicant
argues that the design element in its mark makes the marks dissimilar. However, the registered mark is in standard characters. A mark
in typed or standard characters may be displayed in any lettering style; the rights reside in the wording or other literal element and
not in any particular display or rendition. See In re Viterra Inc., 671 F.3d 1358, 1363, 101 USPQ2d 1905, 1909 (Fed. Cir. 2012);
In re Mighty Leaf Tea, 601 F.3d 1342, 1348, 94 USPQ2d 1257, 1260 (Fed. Cir. 2010); 37 C.F.R. §2.52(a); TMEP §1207.01(c)(iii).
Thus, a mark presented in stylized characters and/or with a design element generally will not avoid likelihood of confusion with a mark
in typed or standard characters because the word portion could be presented in the same manner of display. See, e.g., In re
Viterra Inc., 671 F.3d at 1363, 101 USPQ2d at 1909; Squirtco v. Tomy Corp., 697 F.2d 1038, 1041, 216 USPQ 937, 939 (Fed. Cir.
1983) (stating that “the argument concerning a difference in type style is not viable where one party asserts rights in no particular
display”).

    15

     

    

Additionally,
when evaluating a composite mark consisting of words and a design, the word portion is normally accorded greater weight because it is
likely to make a greater impression upon purchasers, be remembered by them, and be used by them to refer to or request the goods and/or
services. In re Aquitaine Wine USA, LLC, 126 USPQ2d 1181, 1184 (TTAB 2018) (citing In re Viterra Inc., 671 F.3d 1358, 1362,
101 USPQ2d 1905, 1908 (Fed. Cir. 2012)); TMEP §1207.01(c)(ii). Thus, although marks must be compared in their entireties, the word
portion is often considered the dominant feature and is accorded greater weight in determining whether marks are confusingly similar,
even where the word portion has been disclaimed. In re Viterra Inc., 671 F.3d at 1366-67, 101 USPQ2d at 1911 (citing Giant
Food, Inc. v. Nation’s Foodservice, Inc., 710 F.2d 1565, 1570-71, 218 USPQ2d 390, 395 (Fed. Cir. 1983)).

 

Applicant
argues that the marks are different in sound, connotation and meaning/commercial impression. However, the dominant element DUO is identical
in the marks. Thus, the sound, meaning and commercial impression of the most important commercial impression creating element in
the marks is identical. Thus, the marks are similar.

 

Next,
the evidence of record establishes that the goods are highly related. The compared goods and/or services need not be identical or even
competitive to find a likelihood of confusion. See On-line Careline Inc. v. Am. Online Inc., 229 F.3d 1080, 1086, 56 USPQ2d 1471,
1475 (Fed. Cir. 2000); Recot, Inc. v. Becton, 214 F.3d 1322, 1329, 54 USPQ2d 1894, 1898 (Fed. Cir. 2000); TMEP §1207.01(a)(i).
They need only be “related in some manner and/or if the circumstances surrounding their marketing are such that they could give
rise to the mistaken belief that [the goods and/or services] emanate from the same source.” Coach Servs., Inc. v. Triumph Learning
LLC, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting 7-Eleven Inc. v. Wechsler, 83 USPQ2d 1715, 1724
(TTAB 2007)); TMEP §1207.01(a)(i).

 

Attached
to this action are third party web pages which show that it is entirely common for producers of foods for dogs to also produce supplements
for dogs under the same marks and through the same channels of trade. See also evidence attached to first action. Furthermore, attached
to this action are multiple third party registrations showing both supplements and foods for dogs produced under the same marks. Thus,
the evidence of record shows that the goods are highly related. See In re I-Coat Co., 126 USPQ2d 1730, 1737 (TTAB 2018) (citing
In re Infinity Broad. Corp., 60 USPQ2d 1214, 1217-18 (TTAB 2001); In re Albert Trostel & Sons Co., 29 USPQ2d 1783,
1785-86 (TTAB 1993); In re Mucky Duck Mustard Co., 6 USPQ2d 1467, 1470 n.6 (TTAB 1988)); TMEP §1207.01(d)(iii).

 

Applicant
argues that one buying treats for dogs would not mistakenly buy supplements. However, the issue is not likelihood of confusion between
particular goods, but likelihood of confusion as to the source or sponsorship of those goods. In re Majestic Distilling Co., 315
F.3d 1311, 1316, 65 USPQ2d 1201, 1205 (Fed. Cir. 2003); In re Shell Oil Co., 992 F.2d 1204, 1208, 26 USPQ2d 1687, 1689 (Fed. Cir.
1993); TMEP §1207.01. Thus, applicant’s argument is unpersuasive.

 

The
marks are similar. The goods are highly related. Thus, there is a likelihood of confusion and registration must be denied.

    16

     

    

How
to respond.  Click to file a request for reconsideration of this final Office action that fully resolves all outstanding
requirements and refusals and/or click to file a timely appeal to the Trademark Trial and Appeal Board (TTAB) with the required
filing fee(s).

 

/Daniel
F. Capshaw/

Daniel
F. Capshaw

Examining
Attorney

Law
Office 110

571-272-9356

daniel.capshaw@uspto.gov

    17

     

    

SCHEDULE
3

Territory

 

The
exclusive territory shall be the North American pet trade, including online sales to include Mexico, USA and Canada.

 

The
territory excludes the veterinary trade, which includes, but is not limited to veterinary clinics or hospitals, veterinary clinic chains
or corporate veterinary offices, etc. In the event LUCY enters the veterinary trade, the Parties shall consult with each other about
expanding the Territory to include the veterinary trade, and amending this Agreement to memorialize that territorial expansion.

    18

     

    

Schedule
4

 

Lucy
Pet to pay one-time license fee of $100,000 on execution of licensing agreement.

 

Royalty
shall be calculated at 5% of Net Revenue, and payable quarterly. For purposes of this Agreement: (a) “Net Revenue” means,
with respect to the Representative, the total revenues for any period of time from the sale of Products sold by the Representative, less
any: (i) Sampling Expense; and (ii) excise or sales taxes or similar taxes (other than any income or gross receipts tax due to any state
or federal governmental agency with respect to the Representative’s income or gross receipts) due from the Representative with
respect to such total revenues; and (b) “Sampling Expense” means any direct cost of materials, manufacturing, packaging and
delivery incurred by the Representative with respect to Products provided without cost or at a minimal cost to third parties.

19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]